Part IThe 537 Million Problem & Why Data Is the Drug
In 2021, the International Diabetes Federation reported that 537 million adults worldwide were living with diabetes — a number projected to reach 783 million by 2045. Type 2 diabetes accounts for roughly 90 percent of cases, but Type 1, gestational, and other forms collectively affect tens of millions more. The economic burden exceeds $960 billion annually in direct medical costs. The human burden — amputations, blindness, kidney failure, cardiovascular disease, neuropathy — is incalculable.
And yet, for a disease defined by a single measurable molecule — glucose — diabetes management has historically been astonishingly data-poor. A patient might see their endocrinologist every three months, get a single HbA1c reading (a retrospective average of blood sugar over 8-12 weeks), receive a medication adjustment, and return home to manage a 24/7 physiological process with little more than a fingerstick glucometer and their own judgment.
That model is collapsing, and data is what's replacing it. The convergence of continuous glucose monitoring (CGM), wearable insulin delivery systems, AI-driven predictive algorithms, and the richest patient-generated health data streams in the history of medicine is creating an entirely new paradigm: one where the data is the therapeutic intervention, and the analytics framework you apply to it determines whether a patient spends their day in range or in crisis.
The original version of this article, published on PaddySpeaks in February 2024, outlined the skeleton of an analytics and EDA framework for wearable insulin data. This rewrite expands it into a comprehensive treatment: the clinical context, the data engineering, the machine learning models, the closed-loop hardware, the human factors, and the gaps that remain. It is written for endocrinologists, data engineers, biomedical researchers, health informaticists, and anyone building or evaluating the data systems that are redefining what it means to manage diabetes.
Part IIFrom Fingersticks to Continuous Streams
The shift from intermittent blood glucose monitoring to continuous glucose monitoring is not merely an upgrade in resolution. It is a category change in the kind of data available for clinical decision-making. A fingerstick gives you a point. A CGM gives you a curve — typically 288 readings per day (every 5 minutes), generating over 100,000 data points per year per patient. That curve captures post-meal spikes, nocturnal dips, dawn phenomenon rises, exercise-induced drops, and the subtle inter-day variability that HbA1c completely obscures.
The major commercially available CGM systems — Dexcom G7, Abbott FreeStyle Libre 3, Medtronic Guardian 4 with Simplera sensor — all transmit data wirelessly to smartphones and cloud platforms. This creates an unprecedented opportunity for analytics: not just at the individual patient level, but across populations. The ADA's 2026 Standards of Care now explicitly recommend CGM for all insulin-using patients, and evidence is growing for its value in non-insulin-treated Type 2 diabetes as well.
The international consensus on CGM metrics (Battelino et al., 2019; updated 2023) established Time in Range (TIR) — the percentage of time glucose is between 70–180 mg/dL — as a key therapeutic target alongside HbA1c. The recommended targets for most adults: TIR >70%, Time Below Range (TBR <70 mg/dL) <4%, Time Below Range (TBR <54 mg/dL) <1%. These metrics, derivable only from CGM data, are now standard reporting requirements in clinical trials and increasingly in routine practice. For data engineers building analytics pipelines, TIR and its associated metrics (coefficient of variation, Glucose Management Indicator, Glycemia Risk Index) are the primary output variables.
Part IIIThe Metrics That Matter
Understanding the analytics landscape requires fluency in the metrics that clinicians care about. The table below maps the key diabetes management metrics, their data sources, and their analytical implications.
| Metric | What It Measures | Data Source | Analytics Value |
|---|---|---|---|
| HbA1c | Average glucose over 8-12 weeks | Lab blood test | Retrospective summary; misses variability, hypo/hyper events. Still used for regulatory and insurance purposes. |
| Time in Range (TIR) | % time glucose 70–180 mg/dL | CGM | Primary real-time outcome. Each 5% TIR improvement correlates with ~0.5% HbA1c reduction. Primary target: >70%. |
| Time Below Range (TBR) | % time glucose <70 mg/dL | CGM | Safety metric. Target <4%. Critical for closed-loop algorithm tuning and hypoglycemia prediction models. |
| Coefficient of Variation (%CV) | Glucose variability normalized by mean | CGM | %CV >36% = unstable glycemia. Key input for risk stratification and "glucotype" clustering models. |
| Glucose Management Indicator (GMI) | Estimated HbA1c from CGM data | CGM | Bridges CGM metrics and lab values. Useful when lab HbA1c is discordant with daily glucose patterns. |
| Glycemia Risk Index (GRI) | Composite score (hypo + hyper risk) | CGM | Single-number summary of glycemic quality. Useful for population-level dashboards and trend tracking. |
Part IVEDA for the Insulin Switcher: A Data Engineering Framework
One of the most clinically valuable analytics use cases is understanding what happens when a patient switches insulin delivery methods — from multiple daily injections (MDI) to an insulin pump, or from a standalone pump to an automated insulin delivery (AID) system. This is the "insulin switcher" problem, and it requires a structured EDA approach.
Data Preparation
The foundational tables for switcher analytics include: a Patients table (demographics, diagnosis date, comorbidities, insurance status), a Treatments table (treatment type, device model, start/stop dates, reason for switch), a Lab Results table (HbA1c, fasting glucose, lipids — timestamped), a CGM Data table (continuous glucose readings, device ID, wear time), and an Activity/Adherence table (device usage hours, bolus counts, app interactions, carb entries). Data quality is paramount: missing CGM data must be flagged (wear time <70% of days invalidates TIR calculations), lab results need temporal alignment with treatment periods, and treatment start/stop dates must be verified against pharmacy fill records where possible.
The EDA Pipeline
Step 1 — Descriptive statistics: Calculate mean, median, and standard deviation for HbA1c and TIR before and after the switch. Report distributions, not just means — a patient population with mean TIR of 65% might contain a bimodal distribution with one group at 80% and another at 50%, requiring very different interventions.
Step 2 — Visualization: Histograms and kernel density plots for HbA1c change distributions. Boxplots or violin plots comparing pre/post TIR across demographic and clinical segments. Individual patient line charts (spaghetti plots) showing HbA1c trajectories over 12 months — these reveal patterns (rapid improvers, slow responders, deteriorators) that aggregate statistics hide.
Step 3 — Segmentation analysis: Group patients by HbA1c response (improved ≥0.5%, unchanged, deteriorated ≥0.5%). Cross-reference with demographic segments (age, gender, diabetes duration, comorbidities) and behavioral segments (device wear time, bolus frequency, app engagement). Use scatterplots and heatmaps to explore relationships between potential predictors and outcomes.
Step 4 — Deeper analysis: Kaplan-Meier survival curves for time to TIR >70% across segments. Logistic regression or random forest models to identify predictors of treatment success vs. failure. Cox proportional hazards for time-to-event outcomes (time to first severe hypoglycemic episode, time to treatment discontinuation).
Identifying switchers requires temporal join logic: find patients with a treatment record for oral medication (e.g., metformin, identified by NDC code or description) followed by a treatment record for pump/AID therapy, with the pump start date occurring after the oral medication was active. The join should account for overlap periods (patients often titrate off orals while starting pump therapy). A "clean switch" cohort (oral discontinued within 30 days of pump start) and a "transition" cohort (extended overlap) should be analyzed separately.
Part VThe Eight Segmentation Layers
For any wearable insulin switcher analysis, the following segmentation framework provides a comprehensive view of patient outcomes across eight clinical dimensions.
L1: Time to Discontinuation
How long patients stay on wearable insulin before stopping. Kaplan-Meier survival analysis by demographic, clinical, and behavioral segments. Key churn signal.
L2: Time to Complication
Incidence of DKA, severe hypoglycemia, infusion site infections during treatment. Cox regression to identify risk factors.
L3: Glycemic Control
HbA1c and TIR changes post-switch. The primary outcome. Segment by baseline HbA1c to identify who benefits most.
L4: Healthcare Utilization
ER visits, hospitalizations, unscheduled clinic visits. Cost and resource impact of treatment modality change.
L5: Treatment Adherence
Device wear time, bolus frequency, app engagement, CGM sensor changes. Behavioral signal for retention models.
L6: Patient Satisfaction
PRO (patient-reported outcome) data: diabetes distress scores, treatment satisfaction questionnaires. Qualitative overlay.
L7: Cost-Effectiveness
Total cost of care (device + consumables + clinic visits + hospitalizations) compared to prior treatment modality.
L8: Quality of Life
Impact on sleep, work productivity, social participation, caregiver burden. Often the most meaningful metric for patients.
Each layer can be cross-cut by three segmentation types: demographic (age, gender, ethnicity, socioeconomic status), clinical (diabetes type, duration, comorbidities, baseline HbA1c), and behavioral (prior treatment history, technology literacy, engagement patterns). The combination of 8 outcome layers × 3 segmentation types creates a 24-cell analytical matrix — the skeleton of a comprehensive switcher outcomes report.
Part VIAI & Machine Learning in Glucose Prediction
The transition from descriptive analytics (what happened) to predictive analytics (what will happen) is where machine learning transforms diabetes care from reactive to proactive. The core prediction problem: given a patient's CGM history, insulin delivery data, meal/carb inputs, and activity signals, forecast glucose levels 30, 60, or 120 minutes into the future with sufficient accuracy to guide automated insulin delivery.
LSTM (Long Short-Term Memory) networks have emerged as the dominant architecture for glucose time-series forecasting. Their ability to capture long-range temporal dependencies makes them well-suited to the glucose–insulin dynamics problem, where a meal bolus at noon affects glucose at 4 p.m. Research has shown RMSE reductions from 14.55 to 10.23 mg/dL compared to standard stacked LSTM approaches in Type 1 cohorts. Transformer architectures are gaining ground for their ability to process multimodal inputs (CGM + insulin + activity + meal data) simultaneously. Random forests and gradient-boosted trees remain competitive for classification tasks (will the patient go below 70 mg/dL in the next hour?) and for identifying risk factors in structured EHR data. Unsupervised clustering (k-means, DBSCAN) is used to identify "glucotypes" — distinct glucose response profiles that enable patient stratification beyond conventional T1/T2 labels.
Part VIIClosed-Loop Systems: Teaching Machines to Think Like a Pancreas
The ultimate application of glucose prediction models is the automated insulin delivery (AID) system — sometimes called the "artificial pancreas." These systems link a CGM, an insulin pump, and a control algorithm into a closed loop that monitors glucose, predicts trends, and adjusts insulin delivery every 5 minutes, 24 hours a day, without requiring the patient to make manual dosing decisions.
A 2025 meta-analysis across 1,156 subjects found that AI-based closed-loop systems significantly reduced time outside target glucose ranges compared to standard care (standardized mean difference = 0.90, p < 0.001). The ADA's 2026 Standards of Care now recommend AID systems for most people with Type 1 diabetes, and evidence is growing for their use in Type 2 and gestational diabetes as well.
| System | Key Algorithm | TIR (Pivotal Trial) | Notable Feature |
|---|---|---|---|
| Medtronic 780G | SmartGuard (PID + predictive) | ~75% (adults) | Simplera sensor; Vivera 3rd-gen full closed-loop algorithm in trial |
| Tandem Control-IQ | TypeZero (MPC-based) | 74% (adults) | Mobi pump; Android app; expanded dose range 5–200 U/day |
| Omnipod 5 | SmartAdjust (MPC) | ~74% (adults) | Tubeless patch pump; launched Italy Jan 2025; 7-day wear Extended set in development |
| Diabeloop DBLG1 | MPC + self-learning | Varies by pairing | Interoperable with multiple pumps (Kaleido, Dana-i); EU-focused |
| iLet Bionic Pancreas | Proportional-derivative | Data pending at scale | Bi-hormonal (insulin + glucagon) under development; glucagon partnership with Xeris |
Current commercial systems are "hybrid" closed-loop — they automate basal insulin but still require the patient to announce meals and estimate carbohydrates. The frontier is "fully" closed-loop, where the algorithm handles meals autonomously. The Medtronic Vivera algorithm and the OHSU iPancreas system (which integrates fitness sensor data for exercise detection via LSTM-based glucose forecasting) represent this trajectory. A 2026 paper in Advanced Materials introduced the DuoLoop concept — a dual closed-loop system where the first loop is CGM-controlled automated delivery, and the second loop uses glucose-responsive insulin (GRI) whose release rate depends on actual tissue glucose levels, providing a biochemical safety net against algorithm errors.
Part VIIIThe WEAR-ME Study & Wearable Insulin Resistance Detection
Published in Nature in March 2026, the WEAR-ME study represents a landmark in the convergence of wearable data and metabolic medicine. The study enrolled 1,165 participants (median BMI 28, median age 45, median HbA1c 5.4%) and used time-series data from consumer wearable devices (smartwatches) combined with routine blood biomarkers and demographic data to train deep neural networks against a ground-truth measure of insulin resistance (HOMA-IR).
Using a HOMA-IR cut-off of 2.9, the multimodal model achieved an AUROC of 0.80, sensitivity of 76%, and specificity of 84%. This means a consumer smartwatch, combined with a routine blood panel and basic demographic information, can identify insulin resistance — the primary precursor to Type 2 diabetes — with clinically useful accuracy. The implications for population-level screening are profound: instead of requiring expensive, specialized laboratory tests, early identification of at-risk individuals could be done through devices millions already wear.
The WEAR-ME study validates a principle that runs through this entire article: the richest clinical signals are often hidden in the continuous, passive data streams that wearable devices generate. Heart rate patterns, sleep quality, activity levels, and skin temperature — all captured without any effort from the wearer — contain metabolic information that, when combined with even minimal clinical data, enables prediction at a level that was previously accessible only through specialized research facilities.
Part IXClinical Scenario: Raj's First 90 Days
Raj, 34 — Type 1 Diabetes, Switching from MDI to Omnipod 5 AID
Raj has managed his Type 1 diabetes with multiple daily injections for 12 years. His HbA1c has hovered around 8.2% despite good adherence. His endocrinologist recommends switching to the Omnipod 5 automated insulin delivery system with Dexcom G7 CGM.
Week 1 — Onboarding: The system initializes in "learning mode," observing Raj's glucose patterns without making aggressive corrections. TIR: 52%. The algorithm is building a model of Raj's insulin sensitivity, carb ratios, and daily rhythm.
Week 4 — Adaptation: The algorithm has adapted to Raj's dawn phenomenon (glucose rise between 4-7 a.m.) and now increases basal delivery proactively during those hours. Post-meal spikes are being managed with predictive bolus adjustments. TIR: 64%.
Week 8 — Stabilization: Raj has learned to use the "activity" mode before his evening runs. The system's glucose prediction model incorporates his exercise patterns and reduces insulin delivery preemptively, virtually eliminating the post-exercise lows he used to experience with MDI. TIR: 71%. His %CV has dropped from 42% (unstable) to 31% (stable).
Week 12 — Review: Raj's endocrinologist reviews a 90-day CGM report. HbA1c (lab): 7.1% — down from 8.2%. TIR: 73%. TBR: 2.1%. Overnight glucose is remarkably flat. The ambulatory glucose profile shows tight, consistent patterns with minimal hypoglycemia. His diabetes distress score has dropped from 3.8 (high) to 1.9 (low). He sleeps through the night for the first time in years.
In the data pipeline, Raj's case contributes to: L3 (glycemic improvement: HbA1c –1.1%), L5 (adherence: 96% wear time), L6 (satisfaction: distress score –1.9 points), and L8 (QoL: sleep improvement). His data, anonymized and aggregated, feeds the algorithm's population-level learning model, making the system slightly smarter for the next patient who shares his physiological profile.
Part XThe Gaps: Equity, Privacy, and Alarm Fatigue
AID systems cost $6,000–$10,000+ annually for hardware and consumables. Insurance coverage varies dramatically. In the U.S., CGM and pump access is significantly lower among Black, Hispanic, and low-income patients despite comparable or higher disease burden. AI models trained predominantly on data from well-resourced populations may perform poorly for underrepresented groups. A 2026 Frontiers review explicitly called for federated learning approaches that can train models across diverse, decentralized datasets without centralizing sensitive patient data — preserving privacy while improving equity.
Neural networks trained on data from one region or demographic may not transfer to global populations. Dietary patterns, meal timing, activity levels, and insulin sensitivity vary enormously across cultures. The D1NAMO dataset (20 healthy + 9 diabetic individuals) and Shanghai T1DM/T2DM datasets represent early efforts at geographic diversity, but the field needs orders of magnitude more diverse training data.
Closed-loop systems generate alerts: high glucose, low glucose, sensor expiring, infusion set change needed, calibration required. Patients report alarm fatigue as a leading cause of device discontinuation. The physical burden of wearing two devices (CGM + pump) is non-trivial. Usability — sustained time in closed-loop mode >95% — is critical to realizing clinical benefits, and achieving it requires not just good algorithms but good design, good onboarding, and ongoing support.
Data privacy is the other critical concern. CGM data is among the most intimate health information a device can generate — it reveals meal timing, sleep patterns, activity levels, stress responses, and medication adherence. Under HIPAA and GDPR, patients have rights to their data, but the practical reality of data ownership in cloud-connected device ecosystems is complex. Who has access? How long is data retained? Can it be used for research without explicit re-consent? These questions are not theoretical — they shape patient trust and adoption.
Part XIWhere This Is Headed
Digital Twins
Patient-specific computational models that simulate glucose-insulin dynamics, enabling in-silico testing of therapy adjustments before applying them to the real patient. Active digital twins adjust treatment plans in real time based on continuous data streams.
Glucose-Responsive Insulin (GRI)
Smart insulins whose release rate depends on ambient glucose levels — a biochemical closed loop. The DuoLoop system (2026, Advanced Materials) combines GRI with CGM-controlled delivery for dual-layer safety.
Edge AI on Device
AI models trained on cloud data, then compressed and deployed directly onto CGM hardware for real-time, latency-free glucose prediction without internet connectivity.
Multi-Hormonal Systems
Beyond insulin-only: bihormonal systems delivering both insulin and glucagon (iLet Bionic Pancreas) to better mimic the pancreas's natural dual-hormone regulation.
Federated Learning
Training AI models across decentralized hospital and device datasets without centralizing patient data — improving generalizability while preserving privacy and regulatory compliance.
Non-Invasive CGM
Optical, microwave, and bioimpedance-based glucose sensing that eliminates the need for subcutaneous sensors. Still in early-stage validation, but approaching clinical accuracy thresholds.
The ADA now defines Type 2 diabetes "remission" as HbA1c <6.5% maintained for at least 3 months after stopping glucose-lowering medication. AI-driven digital twin systems are being used to model pathways to remission — predicting which combination of lifestyle, pharmacological, and technological interventions can push a specific patient across that threshold. Early trials have shown correlation between digital twin-guided interventions and reductions in blood pressure, cardiovascular risk scores, and medication dependency.
Part XIIThe Pancreas We Can Build
The pancreas is an organ of exquisite precision. The healthy beta cell detects glucose changes on the order of milligrams per deciliter, computes an appropriate insulin response in seconds, and executes delivery with a specificity that no commercial algorithm has yet matched. It does this without alarms, without calibration, without sensor changes, and without a smartphone app.
We are not there yet. But the trajectory — from fingersticks to CGM, from manual injections to closed-loop algorithms, from HbA1c snapshots to continuous digital phenotyping, from one-size-fits-all dosing to AI-personalized precision — is unmistakable. Each step on this trajectory is a data problem, and each advance has come from treating the data with more sophistication, more intelligence, and more respect for the complexity of human physiology.
For the data engineer, this means building pipelines that can handle high-frequency time-series data at scale, with robust quality checks and real-time processing capabilities. For the endocrinologist, it means learning to interpret ambulatory glucose profiles and CGM-derived metrics as fluently as they read a metabolic panel. For the biomedical researcher, it means designing algorithms that are not just accurate but safe, equitable, and transparent. And for the patient — the person whose body generates all of this data, every day, every minute — it means the possibility of a life where diabetes is managed not by willpower and vigilance, but by a system intelligent enough to carry part of that burden.
That system is being built, right now, by the people reading this article. The analytics framework matters. The data quality matters. The model validation matters. And the human at the center of it all — the person wearing the sensor, the person whose glucose curve tells a story — they matter most of all.